5-Aminolevulinic Acid: The Mitochondrial Compound for Blood Sugar Control

← Back to articles

5-Aminolevulinic acid (5-ALA) is a small amino-acid-like molecule that the body makes inside mitochondria from glycine and succinyl-CoA. It is the first building block of heme, the iron-containing pigment in hemoglobin, myoglobin, and the cytochromes that carry electrons in the cell's energy chain. In recent years, 5-ALA paired with iron (sodium ferrous citrate, or SFC) has been studied as a way to nudge mitochondrial function in people with prediabetes and type 2 diabetes.

The Japanese trial on glucose tolerance

The most-cited human trial is Higashikawa 2013 in Nutrition (PMID 23759263). It randomized 212 mildly hyperglycemic adults (fasting glucose 105–125 mg/dL or HbA1c 6.1–7.1%) to one of three 5-ALA + iron doses or placebo for 12 weeks. The highest-dose arm (15 mg ALA-P + 1.8 mg iron daily) lowered fasting plasma glucose by about 2.3 mg/dL (95% CI 0.24–4.42; p=0.029) and improved 2-hour oral glucose tolerance by about 14.2 mg/dL versus placebo. Importantly, HbA1c, fasting insulin, and HOMA-IR did not change. The effect on glucose handling is real but small; this is a fasting-glucose and post-meal effect, not an HbA1c effect.

Mechanism: feeding the cytochromes

5-ALA pushes more building blocks into the heme pathway, which supports cytochrome c oxidase (Complex IV) and other mitochondrial cytochromes. More efficient electron transport may improve insulin sensitivity in tissues where mitochondrial function is sluggish, such as skeletal muscle and pancreatic beta cells. The iron must be co-supplied because making heme uses iron stoichiometrically; without it, prolonged 5-ALA could deplete iron stores.

Other clinical signals

A 2016 Bahraini pilot trial (Al-Saber 2016, Journal of Diabetes Research; PMID 27738640) tested 5-ALA + SFC up to 200 mg/day in 53 adults with uncontrolled type 2 diabetes. It was primarily a safety study and showed the combination was well tolerated alongside standard antidiabetic drugs. 5-ALA is also the active compound in photodynamic therapy for actinic keratosis and certain cancers, where it accumulates in abnormal cells and is activated by light. Oral supplement doses are far lower than those used for photodynamic therapy.

Safety

At supplement doses of 25–100 mg/day, 5-ALA is generally well tolerated. Mild stomach upset is the most common report. Temporary photosensitivity has been described at higher doses. People with porphyria or hereditary hemochromatosis should avoid 5-ALA because of effects on the heme pathway and iron handling. Anyone already taking iron should keep total intake within recommended limits.